Latest Breaking News On - Perceptive xontogeny venture fund - Page 1 : comparemela.com

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesTufts medical centerDan levangieCarl heilmanPiper sandlerAdel malekEvan greifCompany contactsPrnewswire cerevasc incBain capital life sciencesCerevasc incPerceptive xontogeny venture fundVasc announcesSeriesb financingNormal pressureShunt system

CereVasc Raises $70M in Series B Financing

CereVasc Raises $70M in Series B Financing
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

United statesEvan greifDan levangieBain capital life sciencesPerceptive xontogeny venture fundVice presidentShunt systemNormal pressure

CereVasc raises $70M Series B to support eShunt

CereVasc raises $70M Series B to support eShunt
massdevice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from massdevice.com Daily Mail and Mail on Sunday newspapers.

United statesDan levangiePerceptive xontogeny venture fundBain capital life sciencesCapital life sciences

TORL secures $158m for oncology pipeline development

Clinical-stage biotechnology company TORL BioTherapeutics has announced the closure of an oversubscribed $158m Series B-2 financing round.

Mark allesBristol myers squibbPerceptive xontogeny venture fundDeep track capitalPerceptive advisorsGoldman sachs alternativesMoore strategic venturesVertex venturesBlue owl healthcare opportunitiesAvidity partners

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,.

Dave licataVince ruizRibociclib kisqaliMark allesPalbociclib ibranceDennis slamonPerceptive xontogeny venture fundSlamon research laboratoryBristol myers squibbDivision of hematology oncologyRoth zabelCrandon lawDavid geffen school of medicineDeep track capitalPerceptive advisorsAvidity partners